COVID-19: Is there a role for Western blots and skin testing for determining immunity and development of a vaccine?
COVID-19: Is there a role for Western blots and skin testing for determining immunity and development of a vaccine?
复制标题
DOI：
10.1016/j.diagmicrobio.2020.115148
复制
发表时间：
2020-12-01
影响因子：
2.9
通讯作者：
Wormser, Gary P.
中科院分区：
文献类型：
--
作者：
Pavia, Charles S.;Wormser, Gary P.
严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 病毒感染会刺激免疫反应，该反应可以作为当前或过去接触过该病原体的标记，并可能作为抵抗再次感染的标记。这种对 COVID-19 的反应可以根据抗体的产生进行监测，因此，血清学测试已可用于诊断目的。尽管在这一领域取得了进展，但人们仍然担心太多市售血清学检测系统并不完全可靠。为了解决这个问题，应考虑使用蛋白质印迹法来确认筛查测试（例如 ELISA）的阳性或边缘阳性结果。蛋白质印迹的另一个好处是识别可以构成开发疫苗基础的抗原。关于针对 COVID-19 的细胞介导的免疫反应知之甚少。解决这个问题的一种方法是使用皮肤测试来测量从 COVID-19 中恢复的患者的迟发型超敏反应。 (c) 2020 Elsevier Inc. 保留所有权利。
Infection with the virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) stimulates an immune response which can serve as a marker for current or past exposure to this pathogen, and possibly for resistance to re-infection. This response to COVID-19 can be monitored based on the production of antibodies, and thus, sero-logic tests have become available for diagnostic purposes. Despite progress in this area, concerns have been raised that too many of the commercially available serologic detection systems are not completely reliable. To address this issue, Western blots should be considered for confirming a positive or borderline-positive result from a screening test, such as an ELISA. An additional benefit of Western blots would be to identify antigens that could form the basis for developing a vaccine. Little is known about the cell-mediated immune response against COVID-19. One way to address this would be to use skin testing to measure the delayed-type hypersensitivity response in patients recovering from COVID-19. (c) 2020 Elsevier Inc. All rights reserved.